Exparel(bupivacaine extended-release liposome injection),a non-opioid local analgesic, is FDA approved for post-surgical analgesia. Exparel provides analgesia for several days with...
Pacira BioSciences, Inc. announced that the company’s Marketing Authorization Application (MAA) for Exparel (bupivacaine liposome injectable suspension) for postsurgical analgesia...
Pacira BioSciences, Inc. announced that its Phase IV study of Exparel (bupivacaine liposome injectable suspension) in patients undergoing Cesarean section...
Pacira BioSciences announced that the European Commission has granted marketing authorization for Exparel as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults.
Pacira BioSciences announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for Exparel (bupivacaine liposome injectable suspension) for postsurgical analgesia.
Pacira BioSciences announced positive results from its Phase III PLAY study of Exparel (bupivacaine liposome injectable suspension) administered as a...
Pacira Pharmaceuticals, Inc.announced new data on the use of Exparel (bupivacaine liposome injectable suspension) to manage postsurgical pain following total...
Pacira Pharmaceuticals, Inc. announced the publication of its Phase IV PILLAR study of Exparel (bupivacaine liposome injectable suspension) in total...
Pacira BioSciences announced positive topline results from its Phase III study of Exparel (bupivacaine liposome injection) as a single-dose sciatic nerve block in the popliteal fossa for postsurgical regional analgesia in patients undergoing bunionectomy